Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.42 |
| ▸ | ALPI | P09923 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | TPH1 | P17752 | 3/20 | 0.39 |
| ▸ | GRB2 | P62993 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histidine SCHEMBL8315963 | 1.00 | ITGB3 (0.46) | ITGB3ITGA2BPTPN1SLC7A5PTGS1 | |
| Histidine SCHEMBL8316688 | 1.00 | ITGB3 (0.46) | ITGB3ITGA2BPTPN1SLC7A5PTGS1 | |
| Lysine SCHEMBL18297989 | 0.91 | ITGB3 (0.52) | ITGB3ITGA2BPTPN1SLC7A5PTGS1 | |
| Tryptophan SCHEMBL2689669 | 0.87 | KMT2A (0.57) | ALOX15HIF1AHSD17B10KDM4EADORA3 | |
| Histidine SCHEMBL1996749 | 0.87 | KMT2A (0.57) | ALOX15HIF1AHSD17B10KDM4EADORA3 | |
| SCHEMBL7782151 | 0.86 | SLC1A3 (0.37) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL7782152 | 0.86 | SLC1A3 (0.37) | SLC7A5PTGS1ALPIPKMXIAP | |
| Arginine SCHEMBL8315939 | 0.86 | SLC7A5 (0.40) | ITGB3ITGA2BPTPN1SLC7A5PTGS1 | |
| Arginine SCHEMBL8317787 | 0.86 | SLC7A5 (0.40) | ITGB3ITGA2BPTPN1SLC7A5PTGS1 | |
| Tyrosine SCHEMBL606712 | 0.84 | SLC7A5 (0.65) | ITGB3ITGA2BSLC7A5PTGS1ALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107162855-A | A kind of nutrient matrix cultivated for flower plants and nursery stock and preparation method thereof | 安徽省百思德农业发展有限公司 | 2017-09-15 | — | — | CN | claimed |
| CN-107141134-A | A kind of Vegetable Soil modifying agent and preparation method thereof | 合肥卓畅农业科技有限公司 | 2017-09-08 | — | — | CN | claimed |
| US-9458220-B2 | Single-chain insulin agonists exhibiting high activity at the insulin receptor | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-10-04 | — | — | US | claimed |
| US-20150148520-A1 | SINGLE-CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | UNIV INDIANA RES & TECH CORP (US) | 2015-05-28 | — | — | US | claimed |
| US-8610058-B2 | Silver and silver nanoparticle MALDI matrix utilizing online soft landing ion mobility | UNIVERSITY OF NORTH TEXAS (US) | 2013-12-17 | — | — | US | claimed |
| US-20130203665-A1 | SINGLE-CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2013-08-08 | — | — | US | claimed |
| EP-2582719-A2 | SINGLE CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | Indiana University Research And Technology Corporation (US) | 2013-04-24 | — | — | EP | claimed |
| US-20120104243-A1 | Silver and Silver Nanoparticle MALDI Matrix Utilizing Online Soft Landing Ion Mobillity | UNIVERSITY OF NORTH TEXAS (US) | 2012-05-03 | — | — | US | claimed |
| WO-2011159895-A2 | SINGLE CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2011-12-22 | — | — | WO | claimed |
| EP-1620122-A4 | USE OF A PEPTIDE THAT INTERACTS WITH ALPHA V BETA3 INTEGRIN OF ENDOTHELIAL CELL | REGEN BIOTECH INC (KR) | 2009-08-12 | — | — | EP | claimed |
| EP-2029739-A2 | LASE ENZYMES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | Verenium Corporation (US) | 2009-03-04 | — | — | EP | claimed |
| WO-2008118176-A2 | LASE ENZYMES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | VERENIUM CORPORATION (US) | 2008-10-02 | — | — | WO | claimed |
| US-20070004622-A1 | Imidazole derivative, process for producing the same, and use | REGEN BIOTECH, INC. (KR) | 2007-01-04 | — | — | US | claimed |
| EP-1620122-A1 | USE OF A PEPTIDE THAT INTERACTS WITH ALPHA V BETA3 INTEGRIN OF ENDOTHELIAL CELL | Regen Biotech Inc. (KR) | 2006-02-01 | — | — | EP | claimed |
| WO-2004087193-A1 | USE OF A PEPTIDE THAT INTERACTS WITH ALPHA V BETA3 INTEGRIN OF ENDOTHELIAL CELL | REGEN BIOTECH INC.. (KR) | 2004-10-14 | — | — | WO | claimed |
| CN-117903204-A | Design of metalloenzyme based on gene codon extension technology intracellular coding phosphine ligand | 中国科学院生物物理研究所 | 2024-04-19 | — | — | CN | disclosed |
| EP-4301154-A1 | MEAT ALTERNATIVE FORMULATION | Motif Foodworks, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| US-5866683-A | Isoelectric point markers for isoelectric focusing with fluorescence detection | LABORATORY OF MOLECULAR BIOPHOTONICS (JP) | 1999-02-02 | — | — | US | disclosed |
| EP-0744614-A2 | Isoelectric point markers for isoelectric focusing with fluorescence detection | Laboratory of Molecular Biophotonics (JP) | 1996-11-27 | — | — | EP | disclosed |
| WO-1990002812-A1 | METHODS FOR PRODUCING GONADOTROPIN AND TSH SUPER-AGONISTS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 1990-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148520-A1 | SINGLE-CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | IGF1R, GPR119, IRS1 | ITGB3 1945/4885ITGA2B 1712/4885PTPN1 442/4885 |
| US-20130203665-A1 | SINGLE-CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | IGF1R, GPR119, IRS1 | ITGB3 1945/4885ITGA2B 1712/4885PTPN1 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.